Home
button to open the home page
Search Results/
Clinical Outcomes
button to open search results page
Mutations List
button to open mutations list page
Publications
button to open publications page
My Bookmarks
button to open the bookmarks page

Publications

Clinical Trials/Clinical Studies
Collapse Collapse Expand Expand
Brueckl WM et al. Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. Ther Adv Med Oncol. 2021;13:17588359211012361.
de Marinis F et al. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer. 2021;152:127-134.
Janning M, et al. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol. 2022;33(6):602-615.
Miura S. UpSwinG: real-world, non-interventional cohort study on TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations. ELCC 2021. Abstract 145P.
Park K et al. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. BMC Cancer. 2021;21(1):802.
Passaro A et al. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Front Oncol. 2021;11:709877.
Popat S, et al. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). Oncologist. 2022;27(4):255-265.
Tamiya A et al. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study. Anticancer Res. 2017;37(8):4177-4182.
van de Stadt EA et al. Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18 F-afatinib PET/CT imaging. Lung Cancer. 2021;155:156-162.
van Veggel BAMH et al. Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC. 2021 ASCO Annual Meeting. Abstract 9112.
Yang JC et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16:830-838.
Compassionate Use Programme/Expanded Access Programme (CUP/EAP)
Collapse Collapse Expand Expand
Case Studies/Case Series
Collapse Collapse Expand Expand
An N et al. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report. Onco Targets Ther. 2019;12:7399-7404.
Armster K et al. Seltene Mutation im EGFR-Gen: EGFR-CCDC6-Fusion. Spectrum Onkologie. 2021;5:76-77.
Bi H et al. Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review. Ann Transl Med. 2021;9(24):1805.
Cai Y et al. Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report. Medicine (Baltimore). 2019;98:e13890.
Caliman E et al. In regard to "Activity of EGFR TKIs in caucasian patients with NSCLC harbouring potentially sensitive uncommon EGFR mutations". Clin Lung Cancer. 2020. [Epub ahead of print].
Chan RT. Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival. Asia Pac J Clin Oncol. 2018;(Suppl_1):7-9.
Chen D et al. A novel oncogenic driver in a lung adenocarcinoma patient harboring an EGFR-KDD and response to afatinib. Front Oncol. 2020;10:867.
Chen LC et al. A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non-small-cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor. Respirol Case Rep. 2019;7:e00425.
Chiang C-L et al. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation. J Formos Med Assoc. 2020;119(9):1439-1441. 
Chikamori K et al. Treatment experience of a non-small cell lung cancer (NSCLC) patient harboring EGFR minor mutation L747P where afatinib was effective. Jpn J Lung Cancer. 2016;56:665.
Choy TS. First-line TKI treatment in a patient with advanced NSCLC and major uncommon EGFR mutations. MIMS Oncology (Hong Kong). 2021.
Citarella F. Response to: Successful afatinib rechallenge in a patient with nonsmall cell lung cancer harboring EGFR G719C and S768I mutations. Thorac Cancer. 2021 May 11. doi: 10.1111/1759-7714.13997. Online ahead of print.
Coupkova H and Vyzula R. Afatinib in the treatment of advanced non-small cell lung cancer with rare EGFR (in exon 18-T179X) mutation - a case report. Klin Onkol. 2018;31:380-383.
Di Federico A, et al. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter. Clin Cancer Res. 2020;26(2):518-519.
Dongqing LV et al. Response to afatinib in a patient with NSCLC harboring novel EGFR exon 20 insertion mutations. WCLC 2020. Abstract P76.99.
Duan H et al. Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report. Onco Targets Ther. 2018;11:2303-2309.
Endo S et al. A case report of a non-small-cell lung cancer patient who was EGFR-negative on a conventional test but was discovered to have an EGFR uncommon mutation on comprehensive genomic profiling and responded to afatinib. JJLC. 2020;60:429-433.
Fang W et al. Acquired EGFR L718V mutation and loss of T790M-mediated resistance to osimertinib in a patient With NSCLC who responded to afatinib. J Thorac Oncol. 2019;14:e274-e275. 
Fang W et al. Durable response of low-dose afatinib plus cetuximab in an adenocarcinoma patient with a novel EGFR exon 20 insertion mutation. J Thorac Oncol. 2019;14:e220-e221.
Fang W et al. Emergence of EGFR G724S after progression on osimertinib responded to afatinib monotherapy. J Thorac Oncol. 2020;15(3):e36-e37. 
Fang W. Molecular characteristics and response to diverse EGFR TKIs of NSCLC patients harboring EGFR E709 T710delinsX Mutation. WCLC 2020. Abstract P76.47.
Fang W. Molecular characteristics and response to EGFR TKIs of EGFR L747 position mutation in lung cancer patients. WCLC 2020. Abstract P76.40.
Fang YF et al. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report. Thorac Cancer. 2021;12(24):3429-3432.
Frega S et al. A triple rare E709K and L833V/H835L EGFR mutation responsive to an irreversible pan-HER inhibitor: A case report of lung adenocarcinoma treated with afatinib. J Thorac Oncol. 2016;11:e63-e64.
Gallant JN et al. EGFR kinase domain duplication (EGFR-KDD) Is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov. 2015;5:1155-1163.
Galli G et al. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. Lung Cancer. 2018;115:135-142.
Guida A, et al. Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P. Adv Respir Med. 2022;90(3):234-235.
Guo G et al. Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients. Front Oncol. 2021;11:621422.
Guo T et al. Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation. Lung Cancer. 2021;161:94-97.
Han C et al. Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations. J Cancer Res Clin Oncol. 2022. doi: 10.1007/s00432-021-03864-4. Epub ahead of print.
He C, Wang Y. Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report. Mol Clin Oncol. 2022;16(2):30.
Hirose T et al. Extensive functional evaluation of exon 20 insertion mutations of EGFR. Lung Cancer. 2021;152:135-142.
Hochmair MJ et al. Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report. Clin Lung Cancer. 2021:S1525-7304(21)00277-1.
Huang J et al. Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib andosimertinib (AZD9291): A case report. Thorac Cancer. 2018;9(6):745-749.
Huang Q et al. Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib: a case report. Anticancer Drugs. 2021
Ibrahim U et al. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib. Lung Cancer. 2017;108:45-47.
Iida Y et al. Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report. Thorac Cancer. 2019. [Epub ahead of print]. 
Ikeuchi T et al. Successful treatment of lung adenocarcinoma with epidermal growth factor receptor compound mutations involving exon 19 deletion and exon 20 insertion by afatinib. Intern Med. 2019;58:101-104.
Iwamoto Y et al. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation. Jpn J Clin Oncol. 2019;pii:hyz086.
Jelli B et al. Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma. Eur J Case Rep Intern Med. 2021;8(8):002749.
Jiang H et al. EGFR L861Q and CDK4 amplification responding to afatinib combined with palbociclib treatment in a patient with advanced lung squamous cell carcinoma. Lung Cancer. 2020;145:216-218. 
Jiang Y et al. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report. Ann Paliat Med. 2021:apm-20-1477. 
Kate S et al. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer (Auckl). 2019;10:1-10.
Kim Y et al. First-line afatinib for non-small cell lung cancer in real-world practice. J Thorac Oncol. 2017;11(Suppl):S2209.
Kimura S et al. Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay. Cancer Sci. 2018;109:3657-3661.
Kobayashi IS et al. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells. 2021;10(12):3561.
Kobayashi Y et al. EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs. Clin Cancer Res. 2015;21:5305-5313.
Kong C et al. Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: a case report. BMC Pulm Med. 2020;20(1):135.
Kulkarni AA, et al. Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC. Lung Cancer Manag. 2022;11(1):LMT54.
Kunimasa K et al. Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient. Lung Cancer. 2020;148:28-32.
Kunimasa K, et al. Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report. Invest New Drugs. 2022. doi: 10.1007/s10637-022-01264-0. Epub ahead of print.
Kutsuzawa N et al. Successful treatment of a patient with lung adenocarcinoma harboring compound EGFR gene mutations, G719X and S768I, with afatinib. Tokai J Exp Clin Med. 2020;45(3):113-116.
Li N, et al. Pedigree analysis of the EGFR p.V1010M germline mutation in a family with a family history of non-small-cell lung cancer. Ann Transl Med. 2022;10(3):154.
Li T et al. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thorac Cancer. 2021
Li Y et al. Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib. Transl Lung Cancer Res. 2020;9(5):2188-2190.
Liang SK et al. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer. 2019;133:103-109.
Liang SK et al. Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. Oncotarget. 2017;8:90430-90443.
Lin L et al. Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations. Onco Targets Ther. 2020;13:9753-9757.
Liu Y, et al. Lung adenocarcinoma harboring triple rare EGFR exon18 mutations rapidly developed resistance to multiple therapies. Chemotherapy. 2022. doi: 10.1159/000525623. Epub ahead of print.
Long X et al. Great efficacy of afatinib in a patient with lung adenocarcinoma harboring EGFR L833V/H835L mutations: A case report. Onco Targets Ther. 2020;13:10689-10692.
Long Y et al. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report. Ann Palliat Med. 2020. [Published online ahead of print.]
Longo V et al. Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib. Thorac Cancer. 2021 May 19. doi: 10.1111/1759-7714.13953. Online ahead of print.
Lu Z et al. EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report. Onco Targets Ther. 2021;14:2823-2828.
Lui J et al. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report. BMC Cancer. 2019;19:702. 
Lv D, et al. The effect of afatinib and radiotherapy on a patient with lung adenocarcinoma with a rare EGFR extracellular domain M277E mutation and high PD-L1 expression. J Cancer Res Ther. 2022;18(2):587-589.
Ma C et al. Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report. Medicine (Baltimore). 2020;99(43):e22851.
Ma C et al. Tyrosine kinase inhibitors could be effective against non-small cell lung cancer brain metastases harboring uncommon EGFR mutations. Front Oncol. 2020;10:224. 
Martin J et al. Clinical impact of rare and compound mutations of epidermal growth factor receptor in patients with non-small-cell lung cancer. Clin Lung Cancer. 2019;pii:S1525-7304(19)30103-2.
Masuda et al. Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and 57681 mutations. Thorac Cancer. 2020.  [Online ahead of print.]
Mehta A et al. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis. Cancer Treat Res Commun. 2021;28:100398.
Messeha SS, et al. A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring EGFR L747P Mutation With Clinical Response to Multi-targeted Epigenetic and EGFR Inhibition. Anticancer Res. 2022;42(1):441-447.
Minari R et al. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. Anticancer Drugs. 2021  Mar 5. doi: 10.1097/CAD.0000000000001064. Online ahead of print.
Moran T et al. Clinical activity of afatinib in patients with non-small cell lung cancer harboring uncommon EGFR mutations: a Spanish retrospective multicenter study. Clin Lung Cancer. 2020;S1525-7304(20)30134-0.
Morikawa K et al. A case of advanced adenocarcinoma genetically confirmed with EGFR/BRAF co-mutation in both primary and metastatic lesions. Ther Adv Med Oncol. 2021;13:17588359211053420.
Murano C et al. Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma. EXCLI J. 2019;18:893-898. 
Nakamura T et al. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy. PLoS One. 2018;13:e0209384.
Nasu S et al. Osimertinib treatment was unsuccessful for lung adenocarcinoma with G719S, S768I, and T790M mutations. Intern Med. 2018;57(24):3643-3645.
Ning M et al. Afatinib successfully treated leptomeningeal metastasis of lung adenocarcinoma in a patient with EGFR G719A mutation in detection of cerebrospinal fluid. Chinese Journal of Contemporary Neurology and Neurosurgery. 2020;20(6):551-555.
Niogret J et al. Primary resistance to afatinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutations: S768I and V769L. J Thorac Oncol. 2018;13:e113.
Nuomi T et al. Therapeutic efficacy of osimertinib following afatinib for the rare EGFR mutation exon19 delL747_P753insS: A case report. Respirology. 2021;26:335-335.
Ohara G et al. Long-term survival with afatinib in a patient with lung adenocarcinoma harboring double uncommon EGFR L861Q and G719X mutations. In Vivo. 2020;34(3):1459-1462.
Oyamada Y et al. A Case of Advanced Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptor(EGFR) Exon 20 Insertion, D770_N771insSVD. Gan To Kagaku Ryoho. 2021;48(6):845-847.
Passaro A et al. Activity of EGFR TKIs in caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations. Clin Lung Cancer. 2019;20:e186-e194.
Patil T et al. Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in Stage IV non–small-cell lung cancer. Clin Lung Cancer. 2020;21(3):e191-e204.
Peled N et al. Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer. J Thorac Oncol. 2017;12:e81-e84.
Puskás R et al. Ritka EGFR mutációt hordozó tüdő adenocarcinomában szenvedő beteg hosszútávú kezelése. Medicina Thoracalis. 2016;69:239-242.
Qian Y et al. EGFR-KDD with duplication of exons 18-26 responding to afatinib treatment in a patient with lung adenocarcinoma. WCLC 2020. Abstract P76.21.
Qin BD et al. The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. Onco Targets Ther. 2018;11:4739-4745.
Qin Y et al. Variability of EGFR exon 20 insertions in 24,468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors. Mol Oncol. 2020. [Online ahead of print.]
Qu F et al. An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report. Medicine (Baltimore). 2021;100(45):e27614.
Raez LE et al. EGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations. Clin Lung Cancer. 2021;S1525-7304(21)00072-3.
Raez LE et al. EGFR-RAD51 fusion: A targetable partnership originated from the tumor evolution? J Thorac Oncol. 2018;13:e33-e34.
Robichaux JP. Structural classification of atypical EGFR mutations identifies four major subgroups with distinct patterns of drug sensitivity. WCLC 2020. Abstract MA13.07.
Rossi S et al. Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC. Curr Probl Cancer. 2021.
Rubiera-Pebe R et al. Efficacy of tyrosine kinase inhibitors against lung cancer with EGFR exon 18 deletion: Case report and pooled analysis. Cancer Treat Res Commun. 2021;28:100407.
Saxon JA et al. EGFR L858M/L861Q cis mutations confer selective sensitivity to afatinib. J Thorac Oncol. 2017;12:884-889.
Sehgal K et al. Clinical benefit of tyrosine kinase inhibitors in advanced lung cancer with EGFR-G719A and other uncommon EGFR mutations. Oncologist. 2021;26(4):281-287.
Shen D et al. A novel EGFR G724S and R776H rare co-mutation response to afatinib in a patient with lung adenocarcinoma. WCLC 2020. Abstract P76.06.
Shen YC et al. Comparing the effects of afatinib with gefitinib or erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung Cancer. 2017;110:56-62.
Song Z, et al. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review. Ann Palliat Med. 2022;11(3):1126-1134.
Starrett JH et al. Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations. Cancer Res. 2020. [Epub ahead of print].
Sun C, et al. Successful treatment of Afatinib plus Apatinib using for a lung adenocarcinoma patient with HER-2 V659D mutation: a rare case report. Anticancer Drugs. 2021;32(4):469-473.
Sun L et al. Afatinib in the treatment of brain metastases of lung cancer with one rare EGFR mutation: a two-case report. Anticancer Drugs. 2021.
Tamiya M et al. Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. Invest New Drugs. 2020. [Online ahead of print.]
Tamura T et al. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report. Thorac Cancer. 2021 May 4. doi: 10.1111/1759-7714.13941. Online ahead of print.
Tanaka I et al. Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. Lung Cancer. 2019;127:169-171.
Ullas B, et al. All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations. J Cancer Res Clin Oncol. 2022. doi: 10.1007/s00432-022-04033-x. Epub ahead of print.
Urban L et al. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation. Clin Lung Cancer. 2020;S1525-7304(20)30266-7.
Van Acker L et al. Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report. J Med Case Rep. 2021;15(1):562.
van Kempen LC et al. Afatinib in osimertinib-resistant EGFR ex19del/T790M/P794L mutated NSCLC. J Thorac Oncol. 2018;13:e161-e163.
van Veggel B et al. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer. 2020; 141: 9-13.
Wang X et al. A Novel KIFSB-EGFR Fusion Variant in Non-Small- Cell Lung Cancer and Response to Afatinib: A Case Report. Onco Targets Ther. 2021;14:3739-3744.
Wang XF et al. Afatinib achieved remarkable disease control in a Chinese patient with lung adenocarcinoma harboring rare EGFR exon 18-25 kinase domain duplication. Am J Ther. 2019. [Epub ahead of print].
Watanabe M et al. The effectiveness of afatinib in a patient with advanced lung adenocarcinoma harboring rare G719X and S768I mutations. Intern Med. 2018;57:993-996.
Wei Y et al. Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S. JTO Clin Res Rep. 2021;2(7):100200
Wei Y. et al. A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review. Front Oncol. 2021;11:700345.
Wu JY et al. Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations. Clin Lung Cancer. 2019;20(6):e620-e630.
Wu L et al. Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report. Ann Transl Med. 2022;10(2):116.
Wu SG et al. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Ther Adv Med Oncol. 2020;12:1758835920946156.
Xu H and Shao C. KIF5B- EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma. Onco Targets Ther. 2020;13:8317-8321.
Xu J. Non-small cell lung cancer (NSCLC) patients with rare epidermal growth factor receptor (EGFR) mutations in exons 18 and 19 benefit from treatment with EGFR tyrosine kinase inhibitors. WCLC 2020. Abstract P76.98.
Yamaguchi T et al. Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis. Cancer Treat Commun. 2015;4:169-171.
Yang G et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186-194. 
Yang X et al. Resolving resistance to osimertinib therapy with afatinib in an NSCLC patient with EGFR L718Q mutation. Clin Lung Cancer. 2020;pii:S1525-7304(19)30345-6. 
Yang Y et al. Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report. Front Oncol. 2020;10:542277.
Yu N et al. Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein-Drug Docking. Oncologist. 2021.
Zeng L et al. EGFR exon 18 DelE709_T710insD as an acquired resistance mechanism to afatinib in an advanced EGFR exon 18 E709H lung adenocarcinoma. J Thorac Oncol. 2018;13:e93-e95.
Zeng L et al. Identification of a Novel MET Exon 14 skipping variant coexistent with EGFR mutation in lung adenocarcinoma sensitive to combined treatment with afatinib and crizotinib. J Thorac Oncol. 2019;14:e70-e72.
Zhang C et al. Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review. Thoracic Cancer. 2020. doi:10.1111/1759-7714.13606
Zhang H et al. Responsiveness to full-dose afatinib in a patient with lung adenocarcinoma harboring EGFR S768I and V769L mutations. J Thorac Oncol. 2019;14(2):e25-e27. 
Zhang L, et al. Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases. Front Oncol. 2022;12:861271.
Zhang L-D et al. Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases. Anticancer Drugs. 2021.
Zhang X et al. Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR. Lung Cancer. 2020;S0169-5002(20)30512-2.
Zhang Y et al. Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report. World J Clin Cases. 2021;9(27):8220-8225.
Zhao H et al. Afatinib as a potential therapeutic option for non-small cell lung cancer patients with EGFR G724S. WCLC 2020. Abstract P76.38.
Zhao L et al. Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review. Front Oncol. 2021;11:605853.
Zhao Y et al. Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report. Onco Targets Ther. 2021;14:3063-3067.
Zhao Y et. al. Efficacy of osimertinib in afatinib-resistant lung cancer harboring uncommon EGFR mutations: Case report andliterature review. Clinical Lung Cancer. 2020;S1525-7304(20)30211-4.
Zhou T et al. EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report. J Thorac Dis. 2018;10:E802-E805.
Zhu N et al. A patient of advanced NSCLC with a new EGFR Exon 19 insertion mutation and its response to EGFR-TKIs. J Coll Physicians Surg Pak. 2019;29(12):S126-S128.
Zoechbauer-Muller S et al. Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation. Front Oncol. 2020;10:593852.